Cell Therapy News & Insights | RoslinCT

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing

November 28, 2023

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Industry 4.0 and Advanced Manufacturing

Cell and Gene Therapy, Leadership

November 24, 2023

Industry 4.0 and Advanced Manufacturing

RoslinCT to Present at 2023 Cell & Gene Meeting on the Mesa

Cell and Gene Therapy, Leadership

October 04, 2023

RoslinCT to Present at 2023 Cell & Gene Meeting on the Mesa

RoslinCT Boston Appoints Dean J. Morris, as Chief Operations Officer

Cell and Gene Therapy, Leadership

October 03, 2023

RoslinCT Boston Appoints Dean J. Morris, as Chief Operations Officer

RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board

Cell and Gene Therapy, SAB

August 17, 2023

RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board

Insights about London Climate Action Week

sustainability

June 30, 2023

Insights about London Climate Action Week

RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings

Cell Therapy, cGMP Manufacturing

June 05, 2023

RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings

RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License for their cGMP Manufacturing facilities in Edinburgh, UK

Cell and Gene Therapy, Integration

May 30, 2023

RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License for their cGMP Manufacturing facilities in Edinburgh, UK

Life Sciences in Scotland: How Edinburgh Technopole is Driving Innovation

Cell Therapy

April 20, 2023

Life Sciences in Scotland: How Edinburgh Technopole is Driving Innovation